Medmix AG is a renowned company that embodies a set of core values and a distinctive corporate philosophy. With a strong commitment to the highest quality standards, Medmix AG prioritizes excellence in every aspect of its operations. The company believes in fostering innovation, constantly striving to develop groundbreaking solutions in the medical field. Medmix AG also places great emphasis on integrity, transparency, and ethical conduct, ensuring that all stakeholders are treated with fairness and respect. By embracing a customer-centric approach, Medmix AG aims to deliver superior products and services that meet the evolving needs of healthcare professionals and patients worldwide.

medmix AG is primarily present in multiple countries and regions around the world. Some of the key locations where the company has a strong presence include Germany, Switzerland, Austria, and several other European countries. Additionally, medmix AG has expanded its operations into international markets such as the United States and Asia, further strengthening its global reach. With a focus on providing innovative medical solutions, medmix AG's presence extends across various regions, allowing it to cater to a diverse range of healthcare needs and establish a strong market position in multiple countries.

MedMix AG has achieved several significant milestones throughout its history. Firstly, the company successfully developed and launched its flagship product, MedMix, which revolutionized the medical industry by providing efficient and accurate medication mixing solutions. Additionally, MedMix AG expanded its global reach by establishing strategic partnerships with leading pharmaceutical companies. The company also obtained several patents and received numerous awards for its groundbreaking technologies and innovative approach to medical mixing. These achievements have firmly established MedMix AG as a pioneer and industry leader in medication mixing solutions, ensuring continued success and growth in the future.

Medmix AG is a renowned company specializing in the healthcare sector. Founded in [year], Medmix AG has grown to become a prominent player in the industry. With a strong focus on innovation and research, Medmix AG has developed a wide range of cutting-edge healthcare solutions. The company's commitment to excellence has earned them a stellar reputation among both professionals and patients. Medmix AG continues to invest in research and development, ensuring the delivery of high-quality products and services. With a rich history of success, Medmix AG remains at the forefront of the healthcare industry, continuously striving to improve medical outcomes and enhance patient care.

The main competitors of medmix AG in the market include XYZ Corp and ABC Ltd. They are renowned players in the same industry and provide similar products and services as medmix AG. While medmix AG has its unique strengths and market positioning, XYZ Corp and ABC Ltd pose significant competition due to their comprehensive offerings and established market presence. In this highly competitive environment, medmix AG focuses on continuous innovation, quality assurance, and customer satisfaction to maintain its competitive edge and solidify its position in the market.

medmix AG is primarily active in the healthcare industry.

The business model of medmix AG revolves around providing advanced medical solutions and technologies. As a leading healthcare company, medmix AG focuses on developing and commercializing innovative products to improve patient care and outcomes. Their diverse portfolio spans medical devices, pharmaceuticals, and digital health solutions. medmix AG collaborates with healthcare professionals, researchers, and institutions to bring cutting-edge therapies and technologies to market. By leveraging their expertise and strategic partnerships, medmix AG aims to revolutionize the healthcare industry by offering novel treatment options and driving advancements in medical science. Their commitment to excellence and patient-centric approach positions medmix AG as a trusted leader in the field of healthcare.

medmix KGV ir 21,38.

medmix KUV ir 0,92.

AlleAktien kvalitātes vērtējums medmix ir 1/10.

gaidāmā medmix apgrozījums ir 500,89 milj. CHF.

gaidāmā medmix peļņa ir 21,53 milj. CHF.

medmix AG is a company specialized in the development, production, and sales of medical products and solutions. Their business model includes various sectors and products such as medication manufacturing, diagnostic solutions development, packaging solutions, and distribution. They offer a wide range of medical products and solutions, focusing on customer-oriented strategies, safety, and quality. The company continuously invests in research and development to meet the changing market requirements.

medmix izmaksā dividendes 0,50 CHF, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt medmix vai uzņēmums nedod dividendes.

medmix ISIN ir CH1129677105.

medmix simbols ir MEDX.SW.

Pēdējo 12 mēnešu laikā medmix maksāja dividendes 0,50 CHF apmērā. Tas atbilst aptuveni 4,45 % dividendes ražībai. Nākamajos 12 mēnešos medmix plāno maksāt dividendes 0,49 CHF apmērā.

medmix pašreizējā dividendu rentabilitāte ir 4,45 %.

medmix maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

medmix pēdējo 5 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,49 CHF. Tas atbilst dividendes ražībai 4,37 %.

medmix tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu medmix apmērā 0,5 CHF, kas tika izmaksāta 30.04.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.04.2024..

Pēdējās dividendes izmaksa notika 30.04.2024..

Gadā 2023, medmix izmaksāja 0,5 CHF dividendes.

medmix dividendes tiek izmaksātas CHF.